[Editor's note].
Since the beginning of this year, Jiangsu's economic operation has generally rebounded and improved, with steady progress, and various business entities have played an important role. Following the series of "Su Xiaotong Takes You to See Jiangsu", Jiangsu Statistics once again launched the column "Su Xiaotong Takes You to See Enterprises", focusing on the characteristics and highlights of the operation of key enterprises, looking at "enterprise development" from a "statistical perspective", expanding the field of statistical services, and taking business entities as the object, using detailed data and examples to introduce the obvious progress it has made in innovative development and green development, so as to build momentum for solid promotion of high-quality development.
In 2023, it will achieve sales of 1 billion yuan".
One of the top 30 manufacturing enterprises in Huai'an City".
Hello everyone! I amSu Xiaotong
In this issue of "Look at Enterprises", we will walk into it together.
Chia Tai Qingjiang Pharmaceutical
As Huai'an pharmaceutical manufacturing industry, from singles to clusters.
A historical witness from tradition to innovation.
It has made outstanding contributions to the high-quality development of local economy and society.
Founded in 1970, Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. is a historical witness of Huai'an's pharmaceutical manufacturing industry from singles to clusters, from tradition to innovation. After more than 50 years of development, the company has gradually developed into a large-scale modern pharmaceutical enterprise integrating R&D, production and sales, with sales of 1 billion yuan in 2023, a year-on-year increase of 3%; Profits and taxes 2300 million yuan, an increase of 21%, listed as one of the top 30 manufacturing enterprises in Huai'an, and made outstanding contributions to the high-quality development of local economy and society.
Benefit from innovation
Scientific and technological innovation is the first driving force to lead development, and it is also an important focus to promote the transformation and upgrading of enterprises. CP Qingjiang Pharmaceutical has always adhered to scientific and technological innovation as the first driving force for enterprise development, and has continuously increased its R&D investment since 2011, with an annual R&D investment of about 60 million yuan, accounting for more than 6% of sales revenue.
Especially since 2021, the company's R&D investment has been strengthened again, with the average annual R&D investment accounting for 8% of sales revenue, and more than 10% for the first time in 2023. It has successively set up R&D centers in Huai'an and Nanjing, and built 7 innovation platforms, including the National Postdoctoral Research Workstation, Jiangsu Orthopedic Drug Engineering Technology Research Center, Jiangsu Enterprise Technology Center, Jiangsu Orthopedic Sustained-Release Technology Research Engineering Center, Jiangsu Postdoctoral Innovation Practice Base, Jiangsu Enterprise Graduate Workstation and Huai'an Key Laboratory, and cooperated with China Medical University, Nanjing University of Traditional Chinese Medicine and other scientific research institutes to form an innovation system with deep integration of production, education and research, and the technical strength has been continuously enhanced. It was recognized as the first batch of "R&D Institutions of Key Enterprises in Jiangsu Province".
With the high investment of innovation, the high output of the results is followed. Driven by a series of innovative elements, CT Qingjiang continues to implement the R&D strategy of "combination of imitation and innovation", continuously cultivates and develops new kinetic energy, and has formed a rich technology accumulation and invention patent layout in the new crystal form, synthesis route, preparation process, detection method, impurity control and other aspects of drugs. In 2023, the company will have 1 Category 1 innovative drug to initiate phase 1 clinical trials, and 2 Category 1 innovative drugs to conduct preclinical studies; It has a total of 78 valid patents and patent applications, and more than 40 high-end generic drugs are under development. In 2023, the company's operating income increased by 3% year-on-year, profits increased by nearly 40%, and sales of high-tech and patented products accounted for more than 85%, of which the sales of exclusive products Clojixin in the terminal market soared by 300%, firmly occupying a dominant position in the market.
Promote development with talents
Talent is the driving force to promote scientific and technological innovation, and it is also the fundamental element for enterprises to accelerate their development. Over the years, CT Qingjiang has adhered to the development concept of "understanding people, respecting people, relying on people, uniting people, and cultivating people", and has taken multiple measures to "build nests and attract phoenixes". The company deepens the reform of the talent training mechanism, innovates and builds a first-class training system, completely opens up the talent promotion channel, and cultivates, introduces and makes good use of talents in an all-round way. Since 2022 alone, it has attracted 1 deputy general manager and 6 director-level high-level talents who originally worked in industry leading companies to join. In 2023, he will be awarded the "Outstanding Contribution Award for Staying in Huai'an for Employment" in Huai'an City.
By the end of 2023, there are 426 employees with bachelor's degrees in CP Qingjiang, accounting for 43% of the total number of employees; There are 39 people with master's degree or above, and 182 people in R&D, quality and other technical positions; Among the R&D team members, 8 people have been selected into the provincial talent plans such as the "333" project in Jiangsu Province and the "Six Talents" peak in Jiangsu Province. In 2023, the company will introduce nearly 100 fresh college graduates majoring in medicine, most of whom have completed pre-job training and invested in front-line production and R&D work, injecting new vitality and vitality into the innovation and development of the company.
"Digitalization" empowers and increases efficiency
Starting in 2021, CT Qingjiang began to launch a digital transformation strategy, with an annual sales revenue of 0In the past three years, a total of nearly 20 million yuan has been invested to develop and establish a number of digital platforms such as customer relationship management system (CRM), office automation system, warehouse management system (WMS), and Finesoft reporting system. The technical transformation and installation of several granules equipment in the solid preparation workshop has increased the production efficiency of the bottle and package linkage line of glucosamine hydrochloride tablets and other main products by 30%, and promoted the company's production capacity to achieve a significant increase.
Through a series of digital project transformation, the company has connected all business units such as R&D, procurement, production and sales, realized real-time data transmission and sharing, facilitated the analysis and decision-making of managers at all levels, tapped potential and reduced costs, and significantly improved operational efficiency. From 2021 to 2023, the cost of enterprise sales expenses and management expenses has decreased significantly, providing a strong guarantee and support for the transformation and innovation development. Thanks to the outstanding results of digital empowerment, CT Qingjiang has been awarded the "Pilot Enterprise for the Integration of Industrialization and Industrialization in Jiangsu Province" and "Demonstration Enterprise for Innovation Capacity Building of Small and Medium-sized Enterprises in Jiangsu Province".
By the end of 2023, the new factory of Zhengda Qingjiang Pharmaceutical, covering an area of more than 180 acres and with a total investment of about 2 billion yuan, has been officially completed and put into operation, and after the production capacity is fully released, it will form an annual production capacity of 6 billion tablets of various preparations and drugs, and can achieve an annual sales revenue of 3 billion yuan and a profit and tax of 500 million yuan.